Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

Rachel Woodford; Yanni Loh; Joanna Lee; Wendy Cooper; Ian Marschner; Craig R. Lewis; Michael Millward; Sally Lord; Richard J. Gralla; James C.H. Yang; Tony Mok; Chee K. Lee

doi:10.2217/fon-2019-0105

Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

Rachel Woodford, Yanni Loh, Joanna Lee, Wendy Cooper, Ian Marschner, Craig R. Lewis, Michael Millward, Sally Lord, Richard J. Gralla, James C.H. Yang, Tony Mok, Chee K. Lee

Medicine

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

Original language	English (US)
Pages (from-to)	2371-2383
Number of pages	13
Journal	Future Oncology
Volume	15
Issue number	20
DOIs	https://doi.org/10.2217/fon-2019-0105
State	Published - Jul 2019

Keywords

PD-L1 expression
chemoimmunotherapy
meta-analysis
non-small-cell lung cancer
progression-free survival

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2019-0105

Cite this

@article{4bebf76ceb2245d8aca27bc3be8b0a54,

title = "Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer",

abstract = "We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.",

keywords = "PD-L1 expression, chemoimmunotherapy, meta-analysis, non-small-cell lung cancer, progression-free survival",

author = "Rachel Woodford and Yanni Loh and Joanna Lee and Wendy Cooper and Ian Marschner and Lewis, {Craig R.} and Michael Millward and Sally Lord and Gralla, {Richard J.} and Yang, {James C.H.} and Tony Mok and Lee, {Chee K.}",

note = "Publisher Copyright: {\textcopyright} 2019 Future Medicine Ltd.",

year = "2019",

month = jul,

doi = "10.2217/fon-2019-0105",

language = "English (US)",

volume = "15",

pages = "2371--2383",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "20",

}

TY - JOUR

T1 - Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

AU - Woodford, Rachel

AU - Loh, Yanni

AU - Lee, Joanna

AU - Cooper, Wendy

AU - Marschner, Ian

AU - Lewis, Craig R.

AU - Millward, Michael

AU - Lord, Sally

AU - Gralla, Richard J.

AU - Yang, James C.H.

AU - Mok, Tony

AU - Lee, Chee K.

PY - 2019/7

Y1 - 2019/7

N2 - We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

AB - We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

KW - PD-L1 expression

KW - chemoimmunotherapy

KW - meta-analysis

KW - non-small-cell lung cancer

KW - progression-free survival

UR - http://www.scopus.com/inward/record.url?scp=85070102898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070102898&partnerID=8YFLogxK

U2 - 10.2217/fon-2019-0105

DO - 10.2217/fon-2019-0105

M3 - Review article

AN - SCOPUS:85070102898

SN - 1479-6694

VL - 15

SP - 2371

EP - 2383

JO - Future Oncology

JF - Future Oncology

IS - 20

ER -

Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this